Best Peptides for Women: Weight, Skin, Sleep, Libido & Menopause

Key takeaways

• The peptides with the strongest evidence in women are prescription drugs, not wellness products: the GLP-1 drugs for weight (women were 74% of the semaglutide STEP 1 trial and 68% of the tirzepatide SURMOUNT-1 trial) and the bone drugs teriparatide and abaloparatide, which cut fracture risk in postmenopausal osteoporosis.
• Bremelanotide (PT-141) is the only peptide approved for a women-specific use, low sexual desire before menopause. The effect is small, 40% of women get nausea, and it was not studied after menopause.
• Topical GHK-Cu is a cosmetic with thin human evidence. Sermorelin raises growth hormone in women, but the one trial that enrolled women found the lean-mass, well-being and libido gains went to the men and sleep did not change in anyone. DSIP has no modern evidence and cannot be legally compounded.
• No peptide treats menopause. Menopausal hormone therapy is the most effective treatment for hot flashes and genitourinary symptoms and prevents bone loss; no peptide has been tested for any menopausal symptom. No peptide has human evidence for hair loss in women.
• Every compound here carries a pregnancy warning. GLP-1s and bremelanotide must be stopped when pregnancy is recognized, tirzepatide reduces the absorption of oral contraceptives, and abaloparatide is not indicated for women who could become pregnant.

How we ranked

We ranked by four things, in this order: the evidence in women specifically (graded A to D as in our compound profiles), legality in the United States as of October 2026 (approved drug, legally compoundable, or neither), safety, and cost. Popularity did not count. That ordering produces an honest but unglamorous list: the top two entries are drugs your doctor already knows, and three of the seven goals women ask about have no peptide with evidence behind them.

A note on the word: semaglutide, tirzepatide, teriparatide, abaloparatide and bremelanotide are peptide drugs that went through FDA review; sermorelin is a compounded peptide with an approval history; GHK-Cu is a cosmetic ingredient; collagen "peptides" are a food supplement and are not covered (see what are peptides).

The ranking

1. Weight: semaglutide and tirzepatide

If weight is the goal, the question is which GLP-1 drug, and the trials that settled it were mostly trials of women. STEP 1 enrolled 1,961 adults with obesity or overweight and no diabetes; 1,453 of them, 74%, were women. Semaglutide 2.4 mg once a week for 68 weeks produced a mean weight loss of 14.9% against 2.4% on placebo, 86% lost at least 5% and half lost at least 15%, with nausea and diarrhea common and 4.5% stopping for gut symptoms (Wilding 2021). SURMOUNT-1 enrolled 2,539 adults, 1,714 of them women (68%), and tirzepatide at 5, 10 and 15 mg weekly for 72 weeks produced losses of 15.0%, 19.5% and 20.9% against 3.1% on placebo; 57% of the 15 mg group lost a fifth of their body weight (Jastreboff 2022). No other peptide sold for weight loss has data of that kind in anyone.

PCOS. Women with PCOS ask about GLP-1s more than any other group, and the evidence is thinner than the hype. The 2023 international PCOS guideline says that anti-obesity medications including liraglutide and semaglutide "could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines," adds that contraception must be ensured because pregnancy safety data are lacking, and warns of weight regain after stopping (Teede 2023). The semaglutide trial most often quoted is a 2025 open-label study of 100 overweight or obese women with PCOS randomized to metformin alone or metformin plus semaglutide 1 mg weekly for 16 weeks: the combination group lost 6.1 kg against 2.3 kg, with lower testosterone and C-reactive protein, more menstrual recovery, and, in a later metformin-only phase, a higher natural pregnancy rate (35% versus 15%) (Chen 2025). It is a small, unblinded trial at a low dose, and it is the best there is.

Legal status and cost. Both drugs are approved; compounded copies are legal only for a patient with a documented need the approved product cannot meet, and FDA sent 55 warning letters to telehealth companies in 2026 over their marketing. Wegovy is $349 a month ($199 for the first two fills for new patients), Zepbound $299 to $449 by dose, compounded semaglutide $150 to $350; see the compounded semaglutide versus tirzepatide guide and the cost guide.

Pregnancy and breastfeeding. Weight loss offers no benefit in pregnancy and may harm the fetus; both labels say to stop the drug when pregnancy is recognized. Tirzepatide slows stomach emptying enough to reduce the absorption of oral contraceptives, and the Zepbound label tells women on the pill to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase; a single-dose lactation study found tirzepatide undetectable or low in breast milk, with no data on the infant (Zepbound label).

Who it is for: adults with a BMI of 30 or more, or 27 or more with a weight-related condition, including women with PCOS and higher weight, expecting long-term use. Not for the last five pounds, and not from a vendor's vial.

2. Bone: teriparatide and abaloparatide

The parathyroid hormone analogs are the clearest case on this page of a peptide doing something important for women, and they never appear on peptide-clinic menus because they are ordinary drugs for a diagnosed disease.

Teriparatide, the first 34 amino acids of parathyroid hormone, was tested in 1,637 postmenopausal women with prior vertebral fractures. Daily subcutaneous injections of 20 micrograms for a median of 21 months cut new vertebral fractures from 14% to 5% (relative risk 0.35) and new nonvertebral fragility fractures from 6% to 3% (relative risk 0.47), and raised spine bone density by 9 percentage points more than placebo (Neer 2001). Abaloparatide, an analog of parathyroid hormone-related peptide, was tested in the ACTIVE trial of 2,463 postmenopausal women with a mean age of 69: 18 months of daily 80 micrograms reduced new vertebral and nonvertebral fractures compared with placebo and increased bone density at the hip, femoral neck and spine, with less hypercalcemia than open-label teriparatide (3.4% versus 6.4%) (Miller 2016).

Legal status and cost. Both are FDA-approved (Forteo and generic teriparatide; Tymlos), indicated for postmenopausal women with osteoporosis at high fracture risk, with male and glucocorticoid-induced indications added later (Forteo label). Insurers generally cover them for the labeled indication after a bone density scan or a fracture, and there is no reason to obtain either from a compounding pharmacy or a telehealth peptide program.

Pregnancy and breastfeeding. Neither is a drug for women who could become pregnant. The Tymlos label states plainly that abaloparatide is not indicated for females of reproductive potential and has no pregnancy or lactation data (Tymlos label); the Forteo label reports no human pregnancy data, advises considering discontinuation if pregnancy occurs, and says to avoid it while breastfeeding.

Who it is for: postmenopausal women with osteoporosis and a high fracture risk, judged by a clinician with a DXA scan in hand; not a wellness product for anyone else.

3. Libido: bremelanotide (PT-141)

Bremelanotide is the one peptide approved for a women-specific indication, and the detail matters: Vyleesi is for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), meaning low desire that causes distress and is not explained by a medical or psychiatric condition, a relationship problem or a medication (Vyleesi label).

The evidence is two identical 24-week trials in 1,247 premenopausal women with a mean age of 39. Women taking 1.75 mg under the skin as needed before sex reported statistically significant increases in desire and decreases in distress compared with placebo; the integrated differences were 0.35 points on a desire scale that runs from 1.2 to 6, and 0.33 points on a 0-to-4 distress question (Kingsberg 2019). The number of satisfying sexual events did not change, nausea affected 40% versus 1% on placebo, and 18% stopped for side effects versus 2% (Vyleesi label). Grade A for the labeled claim and a small effect by any reading; the PT-141 profile covers the doses studied in women and men and the blood pressure and skin-darkening warnings.

After menopause, bremelanotide has no data. Postmenopausal women were excluded from the trials and the label says the drug is not indicated for them. The option with randomized evidence is transdermal testosterone at doses that reproduce premenopausal female levels: the 2019 global consensus statement, endorsed by eleven societies, found about one additional satisfying sexual event a month over placebo in postmenopausal women with HSDD, with mild acne and hair growth as the side effects, and it does not endorse oral testosterone, pellets, injectables or compounded preparations (Davis 2019). No female testosterone product is approved in the US, so this is off-label use of a fraction of a male gel. Flibanserin (Addyi), a non-peptide pill, had its indication widened in December 2025 to women under 65 regardless of menopausal status.

Legal status and cost. Vyleesi is an approved drug; bremelanotide is legally compoundable because it is the active ingredient of an approved drug, and compounded PT-141 runs $60 to $200 a month. Research-vendor PT-141 was named in FDA's August 2026 warning letters; see the legal tracker.

Pregnancy and breastfeeding. The label requires effective contraception, tells women to stop if pregnancy is suspected, and reports fetal harm in animal studies; there are no data on breast milk.

Who it is for: a premenopausal woman with a clinician-made HSDD diagnosis, normal blood pressure and reliable contraception, willing to trade a chance of nausea for a modest gain in desire and to stop at eight weeks if nothing changes.

4. Skin: topical GHK-Cu

GHK-Cu, the copper tripeptide, is the most-searched peptide for women that is not a drug at all: a cosmetic ingredient in serums and creams whose human evidence is thin in a specific way. A 2026 systematic evidence-mapping review found consistent laboratory data on collagen, matrix remodeling and wound repair but concluded that the clinical evidence "remains sparse": the historical cosmetic reports are small or incompletely characterized, a 13-participant study of GHK-Cu after CO2 laser resurfacing was negative on every objective endpoint, and an 18-participant split-face study in 2026 reported better eyebrow appearance without defining what form of the peptide actually reached the skin (Mateescu 2026). The review calls GHK-Cu "promising but unproven," and a large share of the primary literature comes from the group that discovered the peptide and sold products containing it.

Legal status and cost. Topical GHK-Cu is legal as a cosmetic as long as no drug claims are made. The injectable form came off FDA's Category 2 list in April 2026 but is not on the permitted compounding list, with committee review due by February 2027, so there is no legal injectable GHK-Cu, whatever a clinic's glow menu says; see the GHK-Cu profile and the legal tracker.

Pregnancy and breastfeeding. No studies. Topical exposure is presumably low, but presumably is not data.

Who it is for: a woman who wants a low-risk cosmetic and understands that the evidence is weaker than the marketing. A retinoid and sunscreen have far more behind them.

5. Sleep and body composition: sermorelin, and why DSIP is out

Sermorelin is sold to women for sleep, lean mass, recovery and "menopause," and it does raise growth hormone in women. The best trial of what follows from that is a 16-week placebo-controlled study of a nightly GHRH analog in 10 women and 9 men aged 55 to 71. Overnight growth hormone rose in both sexes, IGF-1 rose within two weeks and had drifted back toward baseline by week 16, and skin thickness increased in both sexes. Everything else went to the men: lean body mass, insulin sensitivity, general well-being and libido improved in men and not in women, and sleep quality, measured by questionnaire, did not change in either sex. The authors concluded that the analog "induced anabolic effects favoring men more than women" (Khorram 1997).

The sleep story is worse than neutral. In sleep-laboratory studies, GHRH given to young men increases deep sleep, but the same hormone given to healthy young women, timed to the menstrual cycle, reduced REM sleep in the first half of the night at the lower dose and reduced stage 4 sleep at the higher dose; the authors wrote that the study "confirms that systemic GHRH impairs sleep in women" (Mathias 2007). That is the hormone itself in a laboratory study rather than a sermorelin treatment trial, but it is the opposite of the claim on the clinic page. Grade B for raising growth hormone, D for sleep in women. The sermorelin profile covers the doses, the IGF-1 monitoring and the gap between studied and prescribed doses.

DSIP (delta sleep-inducing peptide) is excluded on evidence and on law. Isolated from rabbit blood in 1977, it has, in the words of a 2006 review, a link to sleep that "has never been further characterized": no gene or receptor has been found, and the sleep-promoting activity in animals belonged to synthetic analogs rather than DSIP itself (Kovalzon 2006). There are no modern human trials, and in July 2026 FDA's advisory committee voted against adding it (as emideltide) to the compounding list, so no pharmacy may make it; see the DSIP profile.

Legal status and cost. Sermorelin is legally compoundable and costs $150 to $400 a month through telehealth.

Pregnancy and breastfeeding. Not studied; sermorelin should not be used in pregnancy or while breastfeeding.

Who it is for: an adult with a documented low IGF-1 and symptoms of low growth hormone output, prescribed by a clinician who measures the hormone before and after. Not a sleep aid for women; the evidence points the other way.

6. Menopause: no peptide treats it

Searches for sermorelin for menopause exist; trials of peptides for menopausal symptoms do not. No peptide has been tested for hot flashes, night sweats, vaginal dryness or mood changes at menopause; the treatment that has been tested is menopausal hormone therapy. The 2022 position statement of the North American Menopause Society puts it directly: hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and prevents bone loss and fracture; for women under 60 or within ten years of menopause onset without contraindications, the benefit-risk ratio is favorable, while starting later carries greater absolute risks of coronary disease, stroke, clots and dementia; low-dose vaginal estrogen is recommended for genitourinary symptoms when systemic therapy is not indicated (NAMS 2022).

Peptides can address problems that overlap with menopause without treating it: a GLP-1 drug for midlife weight gain, teriparatide or abaloparatide for established osteoporosis, bremelanotide only before menopause. A clinic selling sermorelin or a "menopause stack" for hot flashes is selling something with no trial behind it in place of something with decades of trials.

7. Hair: nothing with human evidence

Copper peptides dominate the "peptide for hair growth" search, and the evidence is cell culture: GHK-Cu and related copper peptides stimulate cultured hair follicles and dermal papilla cells in the laboratory, and the only human data the 2026 review could find for hair was the 18-participant eyebrow study described above (Mateescu 2026). There is no randomized trial of any peptide in female pattern hair loss, and no peptide is approved for it; a pharmacy may compound topical GHK-Cu on prescription, but not on the strength of any hair trial. Topical minoxidil has the trials; iron deficiency, thyroid disease and the hormonal shifts of PCOS and menopause are worth excluding before buying a serum.

Pregnancy and breastfeeding, compound by compound

What we excluded and why

• BPC-157, TB-500 and the Wolverine stack. No human trials in anyone, and as of October 2026 no licensed pharmacy may compound either; the July 2026 committee votes are recommendations FDA has not acted on (legal tracker).
• CJC-1295 and ipamorelin. No female data worth the name; the advisory committee voted against both in late 2024.
• Kisspeptin. The most interesting investigational compound for desire in women, given by intravenous infusion in small brain-imaging studies; not a product any clinician can prescribe, and placed in Category 2 in 2023.
• Melanotan II. Bremelanotide's tanning cousin: never approved anywhere, sold illegally as an injection for years, due for committee review by February 2027.
• AOD-9604, MOTS-c, epitalon and the fat-loss and longevity peptides. No trials in women with outcomes that matter, and no legal supply.
• GLOW, KLOW and other stacks. Combinations of compounds that cannot be legally compounded; see our stack review.
• Collagen peptides and NAD+. A food supplement and a non-peptide, respectively; sold alongside peptides, not peptide therapy.

How to get it

1. Start with the diagnosis, not the compound. Weight, bone density, a desire problem and sleep each have a workup, and the peptide is the last step. A woman with night sweats and poor sleep needs a menopause conversation before a sermorelin prescription.
2. Use a clinician licensed in your state who orders the relevant labs: a bone density scan for osteoporosis drugs, blood pressure and a pregnancy plan for bremelanotide, baseline glucose and a pregnancy plan for GLP-1s, IGF-1 for sermorelin.
3. Ask which pharmacy fills it and on what basis. The GLP-1s and the bone drugs are ordinary prescriptions, often insured; bremelanotide and sermorelin come as brand products or from a state-licensed 503A pharmacy named on the prescription. A research vendor is not a prescription.
4. Price the first three months with the cost guide and compare providers on the same terms in our clinic directory.
5. Agree on a stopping rule before the first dose: eight weeks without benefit for bremelanotide, a repeat IGF-1 at eight to twelve weeks for sermorelin, a weight and side-effect review at each GLP-1 dose step.

Bottom line

The honest list of peptides for women is short and mostly made of drugs with boring names. GLP-1s for weight and parathyroid hormone analogs for bone have large trials in which women were the majority, and they work. Bremelanotide works a little, before menopause, for women who tolerate it. Topical GHK-Cu is a reasonable cosmetic bet with weak evidence. Sermorelin raises growth hormone in women and, in the one trial that checked, delivered its benefits to the men. Nothing on a peptide menu treats menopause, nothing has human evidence for hair, and nothing here is safe in pregnancy. Buy the evidence, not the menu.

Frequently asked questions

+−What is the best peptide for women?

It depends on the goal, and the honest answer is that the best-proven ones are prescription drugs rather than wellness peptides. For weight, semaglutide and tirzepatide have the strongest evidence of any peptide in women, who made up roughly 70% of the pivotal trials. For bone, teriparatide and abaloparatide cut fracture risk in postmenopausal women with osteoporosis. For low desire before menopause, bremelanotide (PT-141) is approved but its effect is small. For skin, topical GHK-Cu is a reasonable cosmetic with thin evidence. For sleep, menopause and hair, no peptide has evidence in women.

+−Which peptides help women lose weight?

The GLP-1 class. In STEP 1, semaglutide 2.4 mg weekly produced an average 14.9% weight loss over 68 weeks versus 2.4% on placebo in 1,961 adults, three-quarters of them women. In SURMOUNT-1, tirzepatide produced 15% to 21% loss over 72 weeks versus 3% on placebo in 2,539 adults, two-thirds women. A small trial in women with PCOS found that adding semaglutide 1 mg to metformin tripled the weight loss over 16 weeks. No other peptide marketed for weight loss, including AOD-9604, MOTS-c and the growth hormone secretagogues, has comparable human data.

+−Can peptides help with menopause?

No peptide has been tested for hot flashes, night sweats, vaginal dryness or the other symptoms of menopause. Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and prevents bone loss and fracture, with a favorable balance of benefit and risk for most women under 60 or within ten years of menopause. Peptides can address specific problems that overlap with menopause, such as weight gain (GLP-1 drugs) or osteoporosis (teriparatide, abaloparatide), but they do not treat menopause itself.

+−What peptide increases female libido?

Bremelanotide (PT-141) is the only peptide approved for low sexual desire, specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder. In two 24-week trials it raised desire scores about 0.3 points more than placebo on a 1.2-to-6 scale and did not increase the number of satisfying sexual events; 40% of women had nausea. It is not approved after menopause. For postmenopausal women with low desire, transdermal testosterone at physiologic female doses has randomized evidence, and flibanserin is now indicated for women under 65.

+−Are peptides safe for women?

The approved ones have the safety data you would expect of a prescription drug: GLP-1s carry a thyroid C-cell tumor warning from rodent studies and cause nausea and other gut effects; bremelanotide raises blood pressure transiently and causes nausea in 40% and skin darkening in some; teriparatide and abaloparatide can raise calcium. Compounded sermorelin has decades of use but no long-term trials in women. Unregulated research peptides have no safety data at all. Every compound on this page carries a pregnancy warning, and most are untested in breastfeeding.

+−Do peptides help women sleep?

There is no evidence that they do, and some that they do not. In laboratory studies, growth hormone-releasing hormone improved deep sleep in men but impaired sleep in women, and the one GHRH-analog trial that enrolled women for 16 weeks found no change in sleep quality in either sex. DSIP, the so-called delta sleep-inducing peptide, has never been shown to have a receptor or a gene, has no modern human trials, and was voted down by FDA's compounding committee in July 2026. If sleep is the problem, treating hot flashes, sleep apnea or insomnia directly has far better evidence.

+−Can you use peptides while pregnant or breastfeeding?

No compound on this page is recommended in pregnancy. The GLP-1 labels say to stop the drug when pregnancy is recognized, and tirzepatide reduces the absorption of oral contraceptives, so a non-oral method or a barrier method is needed for four weeks after starting and after each dose increase. The bremelanotide label requires effective contraception and discontinuation if pregnancy is suspected. Abaloparatide is not indicated for women who could become pregnant, and the teriparatide label advises avoiding it while breastfeeding. Sermorelin, GHK-Cu and DSIP have no pregnancy data at all.

+−Which peptides are best for osteoporosis?

Teriparatide and abaloparatide, the two parathyroid hormone analogs approved for postmenopausal women with osteoporosis at high fracture risk. In 1,637 postmenopausal women with prior vertebral fractures, daily teriparatide 20 micrograms cut new vertebral fractures from 14% to 5% and nonvertebral fragility fractures from 6% to 3% over a median of 21 months. In the 2,463-woman ACTIVE trial, abaloparatide 80 micrograms reduced new vertebral and nonvertebral fractures over 18 months with less hypercalcemia than teriparatide. Both are ordinary prescriptions, usually covered by insurance for the labeled indication.

+−Do peptides help with hair loss in women?

No peptide has human evidence for hair loss in women. Copper peptide (GHK-Cu) shampoos and serums are sold for it on the strength of laboratory studies in cultured hair follicles and, as of 2026, one 18-participant split-face study of eyebrow appearance; there is no randomized trial in female pattern hair loss. Topical minoxidil is the treatment with trials behind it, and iron deficiency and thyroid disease are worth excluding before buying anything.

+−Is sermorelin good for women?

It raises growth hormone in women as it does in men, but the only placebo-controlled GHRH-analog trial that enrolled women, 10 women and 9 men aged 55 to 71 treated for 16 weeks, found that the downstream benefits went to the men: lean mass, insulin sensitivity, well-being and libido improved in men but not in women, and sleep quality did not change in either sex. Skin thickness rose in both. Sermorelin can be legally compounded and costs $150 to $400 a month, but a woman paying for it should know that the trial evidence for women is a negative result.

Sources

1. StudyWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. (2021)
2. StudyJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-16. (2022)
3. StudyChen H et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol 2025;23:108. (2025)
4. GuidelineTeede HJ et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 2023;108:2447-69. (2023)
5. LabelEli Lilly. ZEPBOUND (tirzepatide) injection prescribing information (pregnancy, lactation and oral contraceptive sections), current as of September 2026. DailyMed. (2026)
6. StudyNeer RM et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. (2001)
7. StudyMiller PD et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial (ACTIVE). JAMA 2016;316:722-33. (2016)
8. LabelRadius Health. TYMLOS (abaloparatide) injection prescribing information (indications; not indicated for females of reproductive potential), current as of August 2026. DailyMed. (2026)
9. LabelEli Lilly. FORTEO (teriparatide) injection prescribing information (indications, pregnancy and lactation), current as of August 2026. DailyMed. (2026)
10. StudyKingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899-908. (2019)
11. LabelCosette Pharmaceuticals. VYLEESI (bremelanotide injection) prescribing information, revised March 2024. DailyMed. (2024)
12. GuidelineDavis SR et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab 2019;104:4660-6. (2019)
13. ReviewMateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap (systematic evidence-mapping review). Pharmaceutics 2026;18:1077. (2026)
14. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
15. StudyMathias S et al. Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology 2007;32:1021-7. (2007)
16. ReviewKovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 2006;97:303-9. (2006)
17. GuidelineThe 2022 hormone therapy position statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767-94. (2022)
18. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)